{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-019314","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.407347+00:00","generated_at":"2026-05-26T22:20:34.488248+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IDEAYA reports Q4 2024 net loss of $130.3M; cash ~$1.1B, funds operations into at least 2028","bullets":["Cash, equivalents and marketable securities of ~$1.1B as of Dec 31, 2024, up from $632.6M in 2023.","Net loss for Q4 2024 was $130.3M vs $34.0M in Q4 2023; full-year net loss $274.5M vs $113.0M.","R&D expenses surged to $140.2M in Q4 2024 from $38.8M, driven by $75M upfront for IDE849 license from Hengrui.","Over 230 patients enrolled in darovasertib + crizotinib Phase 2/3 in 1L HLA-A2-negative MUM; median PFS readout by year-end 2025.","Announced three development candidates: IDE892 (PRMT5), IDE034 (B7H3/PTK7 ADC), IDE251 (KAT6/7); INDs targeted in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-019314","json":"https://secwatch.observer/filing/0000950170-25-019314.json","markdown":"https://secwatch.observer/filing/0000950170-25-019314.md","text":"https://secwatch.observer/filing/0000950170-25-019314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017025019314/0000950170-25-019314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017025019314/idya-20250213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:20:34.488248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}